
Demand for a new shot that protects babies against respiratory syncytial virus (RSV) has outpaced supply, prompting U.S. health officials to recommend the doses be saved for high-risk infants. In an alert posted Monday afternoon, the U.S. Centers for Disease Control and Prevention said nirsevimab (Beyfortus) should be reserved for infants with underlying health conditions… read on > read on >